Metabolic Symbiosis‐Blocking Nano‐Combination for Tumor Vascular Normalization Treatment. Issue 17 (26th June 2022)

• Record Type: Journal Article
• Authors: Xiong, Hui; Liu, Xiaoyan; Xie, Zuohan; Zhu, Linyuan; Lu, Haipeng; Wang, Cheng; Yao, Jing
• Is Part Of: Advanced healthcare materials. Volume 11:Issue 17(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-06-26
• Subjects: glycolysis inhibition -- targeted drug delivery -- tumor microenvironment remodeling -- tumor vascular normalization treatment; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202102724
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: The clinical anti‐vascular endothelial growth factor (anti‐VEGF) drugs and metronomic chemotherapy (MET) induced tumor vascular normalization treatment (TVNT) are easily antagonized by tumor microenvironment metabolic cross‐talk between tumor cells and endothelial cells (ECs). To overcome this dilemma, nanodrug with the ability of ECs targeted glycolysis inhibition and nanodrug with the ability of tumor cell glycolysis inhibition, anti‐VEGF, and MET are combined to prepare Nano‐combination the pathways related to angiogenesis, tumor cell proliferation, and immunosuppression and breaking the negative sugar‐lipid‐protein metabolism balance in tumor microenvironment. Thus, stronger and more lasting normalized tumor vascular network and remarkable antitumor efficacy are obtained after treatment, constructing a positive feedback loop between TVNT and anti‐tumor therapy. Above all, this study provides a new insight for solving the bottleneck of clinical TVNT. Abstract : Blocking the metabolic crosstalk between tumor cells and tumor vascular endothelial cells through dual‐nanodrugs shows unique advantages of continuous vascular structure repairment and related improved antitumor effect, which brings a new way to break through the predicament of tumor vascular normalization therapy.